Jefferies notes that the Supreme Court just ruled in favor of the U.S. government in the Kennedy v. Braidwood case, which means HIV PrEP mandated coverage stand and the USPSTF and current recommendations remain in place. The firm, which calls this “an incremental positive” for Gilead (GILD) that removes an overhang going into the launch for Yeztugo, has a Buy rating and $130 price target on Gilead shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Positive Outlook for Gilead Sciences Driven by Favorable Legal Outcomes and Strong Product Launches
- Gilead and Arcus Biosciences’ Promising Phase 3 Cancer Trial Update
- Gilead Sciences Advances Pediatric HIV Treatment with Latest Study Update
- Gilead Sciences Advances Ulcerative Colitis Treatment with GS-1427 Study
- Gilead Sciences’ Promising Phase 3 Study in Endometrial Cancer: A Potential Game-Changer?